452

Compound name
Lorlatinib
Compound Image
Lorlatinib.png
SMILES
CC1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C
MW
406.40
Brutto
C21H19FN6O2
InChI
InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1
InChI Key
IIXWYSCJSQVBQM-LLVKDONJSA-N
Approval Jurisdiction
2018 FDA 2019 EMA
Approved for clinical use
ALK+Ve Met NSCLC
CAS
1454846-35-5
PubChem CID
71731823
Action
ALK /ROS
Approved Drug List
1
Commercial Vendor
Pfizer